Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma.

Ming BaiMeng WangTing DengYuxian BaiKai ZangZhanhui MiaoWenlin GaiLiangzhi XieYi Ba

Published in: Cancer biology & medicine (2022)

SCT200 monotherapy as the second- or further-line treatment for advanced ESCC showed favorable efficacy, with an acceptable safety profile. TP53 mutation abundance might serve as a potential predictive biomarker.

Keyphrases

monoclonal antibody
small cell lung cancer
combination therapy
epidermal growth factor receptor
tyrosine kinase
stem cells
risk assessment
mesenchymal stem cells
climate change
study protocol